drugset

drugset / Trial / NCT00592163

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

NCT00592163 ↗

Phase 1 Completed 20 enrolled Alaunos Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Timeline

Start: 2007-12
Primary completion: 2009-01-04
Completion: 2010-01-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Darinaparsin	Small molecule	200 mg	Oral
Subject	Darinaparsin	Small molecule	900 mg	Oral

Indications